GlobalData on MSN17h
BridgeBio Oncology and Helix enter definitive merger agreement
BridgeBio Oncology has entered a definitive merger agreement with Helix Acquisition Corp II, which will result in the ...
Prediction: BridgeBio Pharma Will Beat the Market. Here's Why
Explore the exciting world of BridgeBio Pharma (NASDAQ: BBIO) with our expert analysts in this Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential ...
The Pharma Letter13h
BridgeBio spin-out in SPAC deal to target RAS and PI3Kα malignancies
BridgeBio Oncology Therapeutics (BBOT), a company advancing small molecule therapeutics targeting RAS and PI3Ka malignancies, ...
Dealbreaker on MSN7h
BridgeBio Oncology to Go Public in SPAC Deal Bringing $450 Million-Plus for Trio of Cancer Drugs
Clinical-stage BridgeBio Oncology Therapeutics, whose financial backers include Cormorant Asset Management, is going public ...
Scotiabank Remains a Buy on Liquidia Technologies (LQDA)
Scotiabank analyst Greg Harrison maintained a Buy rating on Liquidia Technologies (LQDA – Research Report) today and set a price target of ...
Apellis Pharmaceuticals (APLS) Receives a Hold from Scotiabank
Scotiabank analyst Greg Harrison maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report) today and set a price target of ...